Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
7.18
+0.38 (5.59%)
At close: Aug 22, 2025, 4:00 PM
6.87
-0.31 (-4.32%)
After-hours: Aug 22, 2025, 7:02 PM EDT

Company Description

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.

The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.

Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.

Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment.

The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Silexion Therapeutics Corp
Silexion Therapeutics logo
CountryIsrael
Founded2008
IndustryBiotechnology
SectorHealthcare
Employees14
CEOIlan Hadar

Contact Details

Address:
The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr
Jerusalem, 9112001
Israel
Phone972 2 674 3430
Websitesilexion.com

Stock Details

Ticker SymbolSLXN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0002022416
CUSIP NumberG1281K130
ISIN NumberKYG1281K1307
SIC Code2836

Key Executives

NamePosition
Ilan Hadar M.B.A.Chairman and Chief Executive Officer
Mirit Horenshtein HadarExecutive Vice President of Finance Affairs, Chief Financial Officer and Secretary
Dr. Mitchell Shirvan M.B.A., Ph.D.Chief Scientific and Development Officer

Latest SEC Filings

DateTypeTitle
Aug 20, 2025S-8Securities to be offered to employees in employee benefit plans
Aug 20, 20258-KCurrent Report
Aug 19, 20258-KCurrent Report
Aug 12, 2025424B3Prospectus
Aug 12, 2025424B3Prospectus
Aug 12, 2025424B3Prospectus
Aug 12, 202510-QQuarterly Report
Aug 12, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 12, 20258-KCurrent Report
Aug 11, 2025DNotice of Exempt Offering of Securities